Patents by Inventor Rusty L. Montgomery
Rusty L. Montgomery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200318113Abstract: Provided herein are polynucleotide conjugates comprising a polynucleotide and an agent, wherein the polynucleotide comprises a synthetic double stranded miR-29 mimic and the agent facilitates the delivery of the polynucleotide to a cell type or tissue type involved in fibrosis or inflammation. Also provided are methods of making, and uses thereof.Type: ApplicationFiled: March 5, 2020Publication date: October 8, 2020Inventors: Subhadeep Roy, Kurt Vagle, Kevin Rigby, Rusty L. Montgomery
-
Patent number: 10337005Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: GrantFiled: September 13, 2017Date of Patent: July 2, 2019Assignee: MIRAGEN THERAPEUTICS, INC.Inventors: Eva van Rooij, Christina M. Dalby, Rusty L. Montgomery
-
Publication number: 20190127734Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.Type: ApplicationFiled: June 7, 2018Publication date: May 2, 2019Inventors: Rusty L. Montgomery, Christina M. Dalby, Eva Van Rooij, Corrie Gallant-Behm
-
Patent number: 10144930Abstract: The present invention provides nucleic acid inhibitors of MYH7B and compositions thereof. The present invention also provides methods of treating or preventing a cardiac disorder such as cardiac hypertrophy, myocardial infarction, or heart failure in a subject by administering to the subject an inhibitor of MYH7B. The present invention further provides methods of modulating the activity or expression of ?-MHC in cardiac cells of a subject by administering to the subject an inhibitor of MYH7B.Type: GrantFiled: August 24, 2017Date of Patent: December 4, 2018Assignee: MIRAGEN THERAPEUTICS, INC.Inventors: Rusty L. Montgomery, Christina Dalby
-
Publication number: 20180273944Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: ApplicationFiled: September 13, 2017Publication date: September 27, 2018Inventors: Eva van Rooij, Christina M. Dalby, Rusty L. Montgomery
-
Patent number: 9994847Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.Type: GrantFiled: June 7, 2016Date of Patent: June 12, 2018Assignee: MIRAGEN THERAPEUTICS, INC.Inventors: Rusty L. Montgomery, Christina M. Dalby, Eva Van Rooij, Corrie Gallant-Behm
-
Publication number: 20180094262Abstract: The present invention provides nucleic acid inhibitors of MYH7B and compositions thereof. The present invention also provides methods of treating or preventing a cardiac disorder such as cardiac hypertrophy, myocardial infarction, or heart failure in a subject by administering to the subject an inhibitor of MYH7B. The present invention further provides methods of modulating the activity or expression of ?-MHC in cardiac cells of a subject by administering to the subject an inhibitor of MYH7B.Type: ApplicationFiled: August 24, 2017Publication date: April 5, 2018Inventors: Rusty L. Montgomery, Christina Dalby
-
Patent number: 9803202Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: GrantFiled: May 13, 2016Date of Patent: October 31, 2017Assignee: MIRAGEN THERAPEUTICS, INC.Inventors: Eva van Rooij, Christina Marie Dalby, Rusty L. Montgomery
-
Publication number: 20160355815Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.Type: ApplicationFiled: June 7, 2016Publication date: December 8, 2016Inventors: Rusty L. MONTGOMERY, Christina M. DALBY, Eva VAN ROOIJ, Corrie GALLANT-BEHM
-
Publication number: 20160326526Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: ApplicationFiled: May 13, 2016Publication date: November 10, 2016Inventors: Eva van Rooij, Christina M. Dalby, Rusty L. Montgomery
-
Patent number: 9388408Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: GrantFiled: June 21, 2013Date of Patent: July 12, 2016Assignee: miRagen Therapeutics, Inc.Inventors: Eva van Rooij, Christina M. Dalby, Rusty L. Montgomery
-
Patent number: 9376681Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.Type: GrantFiled: September 8, 2015Date of Patent: June 28, 2016Assignee: miRagen Therapeutics, Inc.Inventors: Rusty L. Montgomery, Christina M. Dalby, Eva Van Rooij, Corrie Gallant-Behm
-
Publication number: 20160068842Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.Type: ApplicationFiled: September 8, 2015Publication date: March 10, 2016Inventors: Rusty L. MONTGOMERY, Christina M. DALBY, Eva VAN ROOIJ, Corrie GALLANT-BEHM
-
Publication number: 20130344135Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or niflNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: ApplicationFiled: June 21, 2013Publication date: December 26, 2013Inventors: EVA van ROOIJ, CHRISTINA M. DALBY, RUSTY L. MONTGOMERY
-
Publication number: 20100212036Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class I HDACs, which are known to participate in regulation of chromatin structure and gene expression, have generally been considered as pro-hypertrophic in their action. However, the present invention demonstrates that inhibition of certain Class I HDACs should be avoided in the treatment of cardiac hypertrophy, thereby pointing toward selective, and not global, inhibition of Class I HDACs. In particular, the present invention provides for selective inhibition of HDACs 1 and/or 2, and the avoidance of inhibition of HDAC3.Type: ApplicationFiled: September 29, 2009Publication date: August 19, 2010Inventors: Eric N. Olson, Lawrence Melvin, Rusty L. Montgomery